{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T21:13:34Z","timestamp":1722892414930},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,8,5]],"date-time":"2015-08-05T00:00:00Z","timestamp":1438732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,8,5]],"date-time":"2015-08-05T00:00:00Z","timestamp":1438732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1038\/leu.2015.215","type":"journal-article","created":{"date-parts":[[2015,8,5]],"date-time":"2015-08-05T06:41:01Z","timestamp":1438756861000},"page":"984-987","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Radioimmunotherapy in relapsed\/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial"],"prefix":"10.1038","volume":"30","author":[{"given":"S","family":"Ferrero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Pastore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C W","family":"Scholz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Forstpointner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Pezzutto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Tr\u00fcmper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Finke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U","family":"Keller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Ghione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Passera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W","family":"Hiddemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O","family":"Weigert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Unterhalt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Dreyling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the European MCL Network","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,8,5]]},"reference":[{"key":"BFleu2015215_CR1","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","volume":"27","author":"A Herrmann","year":"2009","unstructured":"Herrmann A, Hoster E, Zwingers T, Brittinger G, Engelhard M, Meusers P et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2009; 27: 511\u2013518.","journal-title":"J Clin Oncol"},{"key":"BFleu2015215_CR2","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1097\/CCO.0b013e328363df0b","volume":"25","author":"S Ferrero","year":"2013","unstructured":"Ferrero S, Dreyling M . The current therapeutic scenario for relapsed mantle cell lymphoma. Curr Opin Oncol 2013; 25: 452\u2013462.","journal-title":"Curr Opin Oncol"},{"key":"BFleu2015215_CR3","doi-asserted-by":"publisher","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","volume":"23","author":"TE Witzig","year":"2005","unstructured":"Witzig TE, Geyer SM, Ghobrial I, Inwards DJ, Fonseca R, Kurtin P et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005; 23: 5347\u20135356.","journal-title":"J Clin Oncol"},{"key":"BFleu2015215_CR4","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","volume":"24","author":"RI Fisher","year":"2006","unstructured":"Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006; 24: 4867\u20134874.","journal-title":"J Clin Oncol"},{"key":"BFleu2015215_CR5","doi-asserted-by":"publisher","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","volume":"27","author":"G Hess","year":"2009","unstructured":"Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma mantle cell lymphoma. J Clin Oncol 2009; 27: 3822\u20133829.","journal-title":"J Clin Oncol"},{"key":"BFleu2015215_CR6","doi-asserted-by":"publisher","first-page":"416","DOI":"10.3324\/haematol.2011.051813","volume":"97","author":"F Zaja","year":"2012","unstructured":"Zaja F, De Luca S, Vitolo U, Orsucci L, Levis A, Salvi F et al. Salvage treatment with lenalidomide and dexamethasone in relapsed\/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers. Haematologica 2012; 97: 416\u2013422.","journal-title":"Haematologica"},{"key":"BFleu2015215_CR7","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1093\/annonc\/mdt366","volume":"24","author":"PL Zinzani","year":"2013","unstructured":"Zinzani PL, Vose JM, Czuczman MS, Reeder CB, Haioun C, Polikoff J et al. Long-term follow-up of lenalidomide in relapsed\/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. Ann Oncol 2013; 24: 2892\u20132897.","journal-title":"Ann Oncol"},{"key":"BFleu2015215_CR8","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369: 507\u2013516.","journal-title":"N Engl J Med"},{"key":"BFleu2015215_CR9","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1002\/cncr.22617","volume":"109","author":"TE Witzig","year":"2007","unstructured":"Witzig TE, Molina A, Gordon LI, Emmanouilides C, Schilder RJ, Flinn IW et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer 2007; 109: 1804\u20131810.","journal-title":"Cancer"},{"key":"BFleu2015215_CR10","doi-asserted-by":"publisher","first-page":"5213","DOI":"10.1200\/JCO.2009.21.8545","volume":"27","author":"M Wang","year":"2009","unstructured":"Wang M, Oki Y, Pro B, Romaguera JE, Rodriguez MA, Samaniego F et al. Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27: 5213\u20135218.","journal-title":"J Clin Oncol"},{"key":"BFleu2015215_CR11","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.","journal-title":"J Clin Oncol"},{"key":"BFleu2015215_CR12","doi-asserted-by":"publisher","first-page":"4336","DOI":"10.1182\/blood.V99.12.4336","volume":"99","author":"GA Wiseman","year":"2002","unstructured":"Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002; 99: 4336\u20134342.","journal-title":"Blood"},{"key":"BFleu2015215_CR13","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.2012.42.2444","volume":"30","author":"MR Smith","year":"2012","unstructured":"Smith MR, Li H, Gordon L, Gascoyne RD, Paietta E, Forero-Torres A et al. Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499. J Clin Oncol 2012; 30: 3119\u20133126.","journal-title":"J Clin Oncol"},{"key":"BFleu2015215_CR14","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.1182\/blood-2013-12-541953","volume":"123","author":"A Kolstad","year":"2014","unstructured":"Kolstad A, Laurell A, Jerkeman M, Gr\u00f8nb\u00e6k K, Elonen E, R\u00e4ty R et al. Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM\/C in non-CR patients before transplant in mantle cell lymphoma. Blood 2014; 123: 2953\u20132959.","journal-title":"Blood"},{"key":"BFleu2015215_CR15","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.3324\/haematol.2013.088377","volume":"98","author":"R Arranz","year":"2013","unstructured":"Arranz R, Garc\u00eda-Noblejas A, Grande C, Cannata-Ortiz J, S\u00e1nchez JJ, Garc\u00eda-Marco JA et al. First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group. Haematologica 2013; 98: 1563\u20131570.","journal-title":"Haematologica"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2015215.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2015215","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/leu.2015.215","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/leu2015215.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T16:15:11Z","timestamp":1648743311000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2015215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,5]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["BFleu2015215"],"URL":"https:\/\/doi.org\/10.1038\/leu.2015.215","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"type":"print","value":"0887-6924"},{"type":"electronic","value":"1476-5551"}],"subject":[],"published":{"date-parts":[[2015,8,5]]},"assertion":[{"value":"5 August 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Off-label use: Zevalin for the treatment of relapsed MCL. SF: Celgene-Mundipharma, Speakers Honoraria. LT: Spectrum Pharmaceuticals, research funding; CWS: Bayer, Speakers Bureau; Spectrum, Membership on an entity\u2018s Board of Directors or advisory committees, Speakers Honoraria. Gilead, Janssen-Cilag, Roche, Pfizer and Mundipharma, Advisory Board; Roche, Mundipharma, Pfizer and Gilead, Speakers Honoraria; UK: Spectrum Pharmaceuticals, Advisory board, Consultancy; Roche, Advisory board, Consultancy. MD: Jannsen-Celgene-Pfizer, Membership on an entity\u2018s Board of Directors or advisory committees, Speakers Bureau, support of ITS; Roche, Speakers Bureau, support of ITS; Mundipharma, support of ITS. The other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}